CA
NZ
UK
AU
IND
US
…
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Champions Oncology provides patient-derived tumor models and preclinical translational testing services to pharmaceutical and biotech clients. Long-term growth could be supported by rising demand for translational models and outsourced preclinical services, and investors may find the company attractive for its niche scientific platform and recurring-service revenue profile.
Key risks include competition from larger CROs and alternative model technologies, customer concentration and revenue timing, and potential capital and execution constraints that investors should monitor.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
| Income before tax | -0.93M | 4.63M | -7.31M | -5.27M | 0.58M |
| Net income | -1.18M | 4.70M | -7.28M | -5.33M | 0.55M |
| Selling general administrative | 11.15M | 9.34M | 11.07M | 10.24M | 9.12M |
| Selling and marketing expenses | 9.32M | 7.54M | 7.06M | 7.00M | 6.38M |
| Gross profit | 28.52M | 26.91M | 20.75M | 24.34M | 25.48M |
| Reconciled depreciation | 1.38M | 1.64M | 1.87M | 2.25M | 1.63M |
| Ebit | -0.93M | 4.65M | -7.28M | -4.45M | 0.61M |
| Ebitda | 0.45M | 6.29M | -5.41M | -1.40M | 2.23M |
| Depreciation and amortization | 1.38M | 1.64M | 1.87M | 3.05M | 1.63M |
| Non operating income net other | - | - | - | -0.01M | -0.02M |
| Operating income | -1.14M | 4.85M | -6.92M | -4.45M | 0.61M |
| Other operating expenses | 60.56M | 52.10M | 57.08M | 58.32M | 48.50M |
| Interest expense | - | 0.03M | 0.03M | - | 0.02M |
| Tax provision | 0.25M | -0.07M | -0.03M | 0.07M | 0.04M |
| Income tax expense | 0.25M | -0.07M | -0.03M | 0.07M | 0.04M |
| Total revenue | 59.42M | 56.94M | 50.16M | 53.87M | 49.11M |
| Total operating expenses | 29.66M | 22.07M | 27.68M | 28.79M | 24.87M |
| Cost of revenue | 30.90M | 30.03M | 29.40M | 29.53M | 23.63M |
| Total other income expense net | 0.21M | -0.22M | -0.39M | -0.82M | -0.02M |
| Net income from continuing ops | -1.18M | 4.70M | -7.28M | -5.33M | 0.55M |
| Net income applicable to common shares | - | - | - | -5.33M | 0.55M |
| Breakdown | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
| Total assets | 26.99M | 32.34M | 26.13M | 34.31M | 35.38M |
| Other current assets | 1.17M | 1.35M | 1.50M | 1.33M | 1.14M |
| Total liab | 22.92M | 28.57M | 28.04M | 29.68M | 26.28M |
| Total stockholder equity | 3.94M | 3.77M | -1.90M | 4.64M | 9.10M |
| Other current liab | 2.67M | 2.69M | 2.31M | 2.42M | 2.49M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -81.07M | -79.89M | -84.59M | -77.32M | -71.98M |
| Other liab | - | - | - | 0.55M | 0.39M |
| Good will | 0.34M | 0.34M | 0.34M | 0.34M | 0.34M |
| Other assets | - | - | - | 0.01M | 0.01M |
| Cash | 4.87M | 9.79M | 2.62M | 10.12M | 9.01M |
| Total current liabilities | 19.92M | 23.85M | 21.54M | 21.73M | 17.48M |
| Current deferred revenue | 8.83M | 15.44M | 12.09M | 12.78M | 11.07M |
| Net debt | -0.36M | -3.68M | 4.81M | -1.52M | 0.46M |
| Short term debt | 1.52M | 1.47M | 1.34M | 1.21M | 1.05M |
| Short long term debt total | 4.51M | 6.11M | 7.43M | 8.60M | 9.47M |
| Other stockholder equity | 84.99M | 83.65M | 82.68M | 81.94M | 81.06M |
| Property plant equipment | - | - | - | 14.50M | 15.36M |
| Total current assets | 19.22M | 22.37M | 13.64M | 19.46M | 19.66M |
| Net tangible assets | - | - | - | 4.30M | 8.76M |
| Net receivables | 13.18M | 11.23M | 9.53M | 8.01M | 9.51M |
| Inventory | - | - | 0.00M | - | - |
| Accounts payable | 6.90M | 4.25M | 5.80M | 5.33M | 2.87M |
| Accumulated other comprehensive income | - | - | 0.00M | - | - |
| Common stock total equity | - | - | - | 0.01M | 0.01M |
| Retained earnings total equity | - | - | - | -77.32M | -71.98M |
| Non currrent assets other | 0.21M | 0.18M | 0.18M | 0.01M | 0.01M |
| Non current assets total | 7.77M | 9.97M | 12.49M | 14.85M | 15.71M |
| Capital lease obligations | 4.51M | 6.11M | 7.43M | 8.60M | 9.47M |
| Breakdown | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
| Investments | - | -0.39M | -0.84M | -2.87M | -2.38M |
| Change to liabilities | - | - | - | 4.03M | 5.97M |
| Total cashflows from investing activities | -0.54M | -0.39M | -0.84M | -2.87M | -2.38M |
| Net borrowings | -0.14M | -0.15M | -0.15M | - | - |
| Total cash from financing activities | 0.10M | 0.17M | -0.53M | 0.01M | 0.21M |
| Change to operating activities | - | - | - | -1.24M | 2.34M |
| Net income | -1.18M | 4.70M | -7.28M | -5.33M | 0.55M |
| Change in cash | -4.91M | 7.17M | -7.50M | 1.09M | 4.32M |
| Begin period cash flow | 9.79M | 2.62M | 10.12M | 9.01M | 4.69M |
| End period cash flow | 4.87M | 9.79M | 2.62M | 10.10M | 9.01M |
| Total cash from operating activities | -4.47M | 7.39M | -6.14M | 3.96M | 6.50M |
| Depreciation | 1.38M | 1.64M | 1.87M | 2.25M | 1.63M |
| Other cashflows from investing activities | 0.02M | - | - | - | - |
| Change to account receivables | -2.00M | -1.44M | -1.99M | 1.31M | -2.82M |
| Sale purchase of stock | - | 0.00M | -0.63M | -0.07M | 0.21M |
| Other cashflows from financing activities | 0.10M | 0.17M | 0.25M | 0.09M | 0.21M |
| Change to netincome | - | - | - | 1.87M | 1.20M |
| Capital expenditures | 0.56M | 0.39M | 0.84M | 2.87M | 2.38M |
| Change receivables | - | - | - | 1.31M | -2.82M |
| Cash flows other operating | - | - | - | -0.14M | -0.03M |
| Cash and cash equivalents changes | - | - | - | 1.11M | 4.32M |
| Change in working capital | -7.37M | -0.62M | -3.82M | 4.23M | 2.34M |
| Stock based compensation | 1.24M | 0.65M | 1.12M | 0.86M | 0.91M |
| Other non cash items | 1.46M | 1.01M | 1.98M | 0.95M | 1.07M |
| Free cash flow | -5.04M | 7.00M | -6.97M | 1.08M | 4.11M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CSBR Champions Oncology Inc |
- -% |
4.81 | - | 22.88 | 1.12 | 17.59 | 1.23 | 185.68 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
One University Plaza, Hackensack, NJ, United States, 07601
201 808 8400
214
| Name | Title | Year Born |
|---|---|---|
| Dr. Ronnie Morris M.D. | Pres, CEO & Director | 1966 |
| Mr. David Barry Miller M.B.A. | Chief Financial Officer | 1969 |
| Dr. Maria Mancini Ph.D. | Chief of Scientific Operations | NA |
| Mr. David DeOrnellis BS, CMAR, CPIA, RLATG | Exec. VP of Global Laboratory Operations | NA |
| Dr. Michael Ritchie M.B.A., Ph.D. | Chief Commercial Officer | NA |
| Dr. Karin Abarca Heidemann Ph.D. | Exec. VP of Global Scientific Operations | NA |
| Dr. Ronnie Morris M.D. | CEO & Director | 1966 |
| Mr. Brady Davis | President | NA |
| Dr. Maria Mancini Ph.D. | Chief Operating Officer | NA |
| Mr. Arthur Hanson | Vice President of Technology | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...